Introduction
The 2007 update of the NHLBI Guidelines emphasizes the key
clinical features that should be assessed to evaluate asthma control,
but the full version is very long. Busy physicians will not want to
wade through the full 415-page document. We present here a concise,
endurable reference containing the important themes of the NHLBI
recommendations and highlighting those areas in which specific and
important changes have been made in the 2007 Guidelines.
Goals and Objectives
At the conclusion of this activity, the participant
should be able to:
- Distinguish between classification of asthma
severity and asthma of control.
- Explain the key clinical features that should
be assessed to evaluate asthma control.
- Recognize when and how to step up or step
down therapy.
- Identify the options for stepping up therapy
for adults and children in different age groups.
- Describe the major recommendations of the
Guidelines.
Target Audience
Primary Care Physicians, Physician Assistants, Registered
Nurses, Nurse Practitioners, and other Allied Health Professionals interested in the treatment of asthma.
Accreditation and Designation Statement
National Jewish Medical and Research Center is
accredited by the ACCME to provide Continuing
Medical Education for physicians.
National Jewish designates this educational activity
for a maximum of 1 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit
commensurate with the extent of their participation
in the activity.
This activity has been reviewed and is acceptable for up
to 2 prescribed credits by the American Academy of
Family Physicians. Of these credits, 1 conforms to the
AAFP criteria for evidence-based CME clinical content.
CME credit has been increased to reflect 2 for 1 credit
for only the EB CME portion. AAFP accreditation
begins 12/01/07. The term of approval is for one year
from this date, with option for yearly renewal. When
reporting AAFP credit, report total Prescribed and
Elective credit for this activity. It is not necessary to label
credit as evidence based CME for reporting purposes.
Disclaimer
The EB CME credit awarded for this activity was based on practice
recommendations that were the most current with the strongest level of evidence
available at the time this activity was approved. Since clinical research is ongoing,
the American Academy of Family Physicians recommends that learners verify sources
and review these and other recommendations prior to implementation into practice.
Participating Faculty
Harold Nelson, MD
Professor
Department of Medicine
National Jewish Medical and Research Center
Professor
University of Colorado Health Science Center
Denver, Colorado
Leonard Fromer, MD, FAAFP
Assistant Clinical Professor
Department of Family Medicine
University of California, Los Angeles
Los Angeles, California
Richard J. Martin, MD, Program Chair
Chairman, Department of Medicine
National Jewish Medical and Research Center
Edelstein Family Chair in Pulmonary Medicine
Professor of Medicine
National Jewish Medical and Research Center
University of Colorado Health Sciences Center
Denver, Colorado
Faculty Disclosure
All faculty in a position to control the content of this
activity are expected to disclose any or no significant
financial interest or other relationship with any
proprietary entity producing health care goods or
services, with the exemption of non-profit or
governmental organizations and non-health care
related companies. Our goal is to ensure that there is
no compromise of the ethical relationship that exists
between those in a position to control the content of
the activity and those attending the activity and their
respective professional duties.
Significant financial interest is defined as receiving,
or in the past twelve months having received, a
salary, royalty, intellectual property rights, consulting
fee, honoraria, ownership interest (e.g., stocks, stock
options or other ownership interest, excluding
diversified mutual funds), or other financial benefit.
KEY
| # Grant Support |
~ Speaker’s Bureau |
| ^ Consultant |
> Other |
David Beuther, MD
# Merck
Ronina Covar, MD
^ AstraZeneca, Merck
# AstraZeneca, Ross Products/Abbott Laboratories
Stephen K. Frankel, MD
Has no significant financial interest to report.
Leonard Fromer, MD
Has no significant financial interest to report
Richard Martin, MD
^ # ~ Altana, GlaxoSmithKline, Teva
^ ~ AstraZeneca, Genentech, Merck, Novartis, sanofi aventis
^ KaloBios, EarlySense
Harold Nelson, MD
^ Curalogic, Dey Laboratories, Dynavax Technologies, Genentech, GlaxoSmithKline, Johnson & Johnson, Novartis, Schering-Plough (Integrated Therapeutics Group)
~ AstraZeneca, GlaxoSmithKline
# Boehringer, Clinical Therapeutics, Genentech, MediciNova, Inc., Sepracor, Inc., Novartis, Schering-Plough (Integrated Therapeutics Group), Teva Pharmaceutical Industries Ltd., Wyeth
Richard W. Weber, MD
^ AstraZeneca, Genentech/Novartis
~ AstraZeneca, Genentech/Novartis, GlaxoSmithKline
# Eli Lilly and Company, GlaxoSmithKline, MannKind Corporation, Pfizer, Inc.
Commercial Support
This program is supported by an unrestricted educational
grant from Schering-Plough.
|
Adobe Acrobat Reader